Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of May 2026, with a report date of May 22, 2026. The filing serves as a notification and public disclosure under the UK Market Abuse Regulation regarding transactions by Persons Discharging Managerial Responsibilities (PDMRs). Haleon operates as a consumer health company with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes and Transactions
The filing details share acquisition transactions executed on May 19, 2026, by two senior executives via dividend reinvestment plans:
- Dawn Allen (Chief Financial Officer): Acquired 2,596.07411 Ordinary Shares on the London Stock Exchange at a price of £3.4022 per share.
- Brian McNamara (Chief Executive Officer):
- Acquired 24,891.04716 Ordinary Shares on the London Stock Exchange at a price of £3.4022 per share.
- Acquired 4,414.93735 American Depositary Shares (ADSs) on the New York Stock Exchange at a price of $9.2446 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of the aforementioned PDMR transactions.
Investor Verification Checklist
- Verify the current share price of Haleon on the London Stock Exchange (LSE) and New York Stock Exchange (NYSE) to confirm the transaction prices of £3.4022 and $9.2446.
- Confirm the total number of shares held by Dawn Allen and Brian McNamara post-transaction to assess their total equity exposure.
- Review the company's most recent quarterly or annual report (Form 20-F) for actual financial performance metrics, as this filing contains none.
- Check for any concurrent announcements regarding dividend declarations that triggered these reinvestment transactions.